Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients
复制标题
DOI：
10.1191/135245800701566331
复制
发表时间：
2000-12-01
期刊：
影响因子：
--
通讯作者：
Simonian, NA
中科院分区：
文献类型：
--
作者：
Fisher, E;Rudick, RA;Simonian, NA
脑萎缩测量可提供对多发性硬化病理过程造成的组织破坏量的估计。萎缩作为疾病进展标志物的潜在有用性取决于萎缩和残疾之间的并发和预测关系。进行了一项随访研究，以测量多发性硬化协作研究组IFN β-1a（Avonex）治疗复发缓解型多发性硬化症的III期试验患者的萎缩和残疾评分。在随机化后约8年，获得了160/172例来自原始试验的合格患者入组随访研究的新数据。随访包括几项测试和问卷调查，包括临床检查以确定扩展残疾状态评分（EDSS）和多发性硬化症功能复合评分（MSFC），以及磁共振成像检查以计算脑实质分数。在可获得数据的四个时间点（基线1年、2年和8年），脑实质分数与EDSS和MSFC均相关。此外，BPF的变化与从III期试验结束到后续VP检查的残疾评分变化相关。这些数据表明，脑萎缩可能是复发缓解型MS疾病进展的有用和临床相关标志物。
Brain atrophy measurement con Provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability A follow-up study was Performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFN beta -1a (Avonex) in relapsing-remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal faction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time Points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-vp exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease Progression in relapsing-remitting MS.